Precisely albumin-hitchhiking tumor cell-activated reduction/oxidation-responsive docetaxel prodrugs for the hyperselective treatment of breast cancer.

Abstract

The anticancer efficacy of chemotherapy is greatly limited by short blood circulation and poor tumor selectivity. Thus, anticancer prodrugs with prolonged systemic circulation, tumor-specific distribution and bioactivation, could significantly strengthen the chemotherapy efficacy. Herein, we design two novel tumor cell reduction/oxidation-responsive docetaxel (DTX) prodrugs, DTX-maleimide conjugates with disulfide bond (DSSM) or thioether bond (DSM) linkages, to evaluate the roles of different sensitive linkages in drug release, pharmacokinetics and therapeutic efficacy. An ester bond-linkage prodrug (DM) is utilized as a non-sensitive control. DSSM and DSM show reduction- or oxidation-sensitive release behavior, respectively, and exhibit hyperselective bioactivation and cytotoxicities between cancerous and normal cells. They could instantly hitchhike blood circulating albumin after i.v. administration with albumin-binding half-lives as short as 1 min, resulting in prolonged systemic circulation, increased tumor accumulation. In response to the upregulated reduction/oxidation environment within tumor cells, DSSM and DSM exhibit selectively release capacity in tumor tissues, their TAITumor/Liver values are over 30-fold greater than DM. Combining the above delivery advantages into one, DSSM and DSM achieve enhanced antitumor efficacy of DTX. Such a uniquely developed strategy, integrating high albumin-binding capability and reduction/oxidation-sensitive drug superselective release in tumors, has great potential to be applied in clinical cancer therapy.

• Authors: Wei Wei, Cong Luo, Jincheng Yang, Bingjun Sun, Dongyang Zhao, Yan Liu, Yingli Wang, Wenqian Yang, Qiming Kan, Jin Sun, Zhonggui He
• Journal: Journal of controlled release : official journal of the Controlled Release Society (J Control Release) Vol. 285 Pg. 187-199 (09 10 2018) ISSN: 1873-4995 [Electronic] Netherlands
• PMID: 30017721 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018. Published by Elsevier B.V.

Chemical References

• Prodrugs
• Serum Albumin
• Docetaxel

Topics

• Animals
• Breast Neoplasms (drug therapy)
• Cell Line, Tumor
• Docetaxel (analogs & derivatives, metabolism, pharmacokinetics, therapeutic use)
• Drug Liberation
• Female
• Humans
• Male
• Mice, Inbred BALB C
• Oxidation-Reduction
• Prodrugs (chemistry, metabolism, pharmacokinetics, therapeutic use)
• Protein Binding
• Rats, Sprague-Dawley
• Serum Albumin (metabolism)
• Tissue Distribution